Education
About Us
Working with TipRanks
Follow Us
Geovax Labs, Inc. (GOVX)
:GOVX
Top Page
GeoVax Labs
(NASDAQ:GOVX)
34Underperform
Positive Factors
Clinical Studies
Additional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.
Comparative Analysis
DSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.
Vaccine Development
GEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Negative Factors
Contract Termination
Termination of the contract will not have a long-term material effect.
Project Termination
GeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.
GeoVax Labs (GOVX) vs. S&P 500 (SPY)
Market Cap
$15.50M
Dividend YieldN/A
Average Volume (3M)400.50K
Price to Earnings (P/E)―
Beta (1Y)3.08
Revenue GrowthN/A
EPS Growth71.39%
CountryUS
Employees17
SectorHealthcare
Sector Strength43
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding15,193,593
10 Day Avg. Volume224,706
30 Day Avg. Volume400,495
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.70Price Target Upside1025.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
GeoVax Labs Business Overview & Revenue Model
Company DescriptionGeoVax Labs (GOVX) is a biotechnology company specializing in developing human vaccines. The company's primary focus is on creating vaccines for infectious diseases, cancer immunotherapy, and other novel treatments by utilizing their innovative MVA-VLP vaccine platform. GeoVax leverages its expertise in vaccine development to address global health challenges, aiming to provide solutions for diseases such as HIV, Zika, Lassa fever, Ebola, and COVID-19.
How the Company Makes MoneyGeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.
GeoVax Labs Financial Statement Overview
Summary
GeoVax Labs faces significant financial challenges with no revenue growth and continuous net losses, reflecting operational and market difficulties. The company's strong cash position offsets some risks, but negative cash flows and reliance on financing indicate potential financial instability.Income Statement
GeoVax Labs has consistently reported zero or negligible revenue, indicating a significant challenge in generating sales. The company has experienced persistent net losses with negative EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to its revenue base.10
Very Negative
Balance Sheet
The balance sheet shows a relatively strong cash position with no debt, which is a positive sign of financial prudence. However, the equity ratio is weak due to a low level of total assets and historical negative equity, posing risks to financial stability and growth potential.25
Negative
Cash Flow
GeoVax Labs exhibits negative operating and free cash flow, indicating potential cash management issues. The company relies heavily on financing activities to support its operations, raising concerns about sustainability and the need for continued external funding.15
Very Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.59M | 3.95M | 0.00 | 81.00K | 385.00K | 1.82M | Gross Profit |
| 1.29M | 3.86M | -20.72M | 24.72K | -15.17M | -621.46K | EBIT |
| -24.67M | -25.14M | -26.74M | -14.03M | -18.75M | -2.82M | EBITDA |
| -24.43M | -24.88M | -26.67M | -13.97M | -18.53M | -2.79M | Net Income Common Stockholders |
| -24.50M | -24.99M | -25.97M | -14.01M | -18.53M | -2.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 571.15K | 5.51M | 6.45M | 27.61M | 11.42M | 9.88M | Total Assets |
| 839.50K | 8.16M | 9.28M | 31.35M | 11.80M | 10.39M | Total Debt |
| 50.00K | 0.00 | 0.00 | 0.00 | 0.00 | 198.06K | Net Debt |
| -521.15K | -5.51M | -6.45M | -27.61M | -11.42M | -9.69M | Total Liabilities |
| 968.40K | 3.11M | 3.52M | 4.75M | 7.43M | 825.00K | Stockholders Equity |
| -128.89K | 5.05T | 5.76M | 26.60M | 4.36M | 9.57M |
| Cash Flow | Free Cash Flow | ||||
| -24.98M | -24.70M | -25.22M | -19.16M | -11.24M | -2.91M | Operating Cash Flow |
| -24.96M | -24.68M | -25.17M | -19.03M | -11.20M | -2.75M | Investing Cash Flow |
| -37.55K | -20.65B | -48.95K | -134.26K | -47.72K | -156.79K | Financing Cash Flow |
| 31.66M | 23.75M | 4.06M | 35.35M | 12.78M | 12.51M |
GeoVax Labs Technical Analysis
Negative
1.04
Price Trends
1.10
Negative
1.52
Negative
2.20
Negative
Market Momentum
-0.03
Negative
53.65
Neutral
88.43
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 1.04 is above the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.10, and below the 200-day MA of 2.20, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 53.65 is Neutral, neither overbought nor oversold. The STOCH value of 88.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.
GeoVax Labs Risk Analysis
GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GeoVax Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.19B | 3.04 | -44.20% | 2.82% | 16.59% | -0.39% | |
45 Neutral | $13.26M | 0.89 | -92.60% | ― | -70.05% | ― | |
44 Neutral | $14.04M | ― | -214.79% | ― | ― | 52.82% | |
43 Neutral | $23.15M | ― | -27.00% | ― | 1904.43% | 93.72% | |
42 Neutral | $8.78M | ― | -76.12% | ― | ― | 81.71% | |
40 Underperform | $8.27M | ― | -64.18% | ― | ― | 1.00% | |
34 Underperform | $15.50M | ― | -616.17% | ― | ― | 71.39% |
* Healthcare Sector Average
Performance Comparison
GOVX
GeoVax Labs
1.04
-0.57
-35.40%
PHIO
Phio Pharmaceuticals
1.83
-5.01
-73.25%
MBRX
Moleculin Biotech
0.98
-3.98
-80.24%
ABVC
ABVC BioPharma
1.37
0.29
26.85%
ADXN
Addex Therapeutics
8.16
-0.56
-6.42%
SNSE
Sensei Biotherapeutics
0.31
-1.09
-77.86%
GeoVax Labs Earnings Call Summary
Earnings Call Date:May 01, 2025
(Q1-2025)
| % Change Since: 2.97%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments in clinical trials and strategic partnerships, juxtaposed with financial challenges and the discontinuation of a significant government contract. While progress in vaccine development is evident, the financial impacts and operational hurdles maintain a level of uncertainty.Q1-2025 Updates
Positive Updates
Robust Vaccine Development Portfolio
GeoVax is progressing with its portfolio, including GEO-CM04S1, GEO-MVA, Gedeptin, and an advanced MVA manufacturing process, addressing unmet healthcare needs and offering expedited registration paths.
GEO-MVA Vaccine Advancements
Completed cGMP production and quality release of GEO-MVA clinical batch, with vaccine availability for clinical evaluation anticipated later in 2025.
Promising Clinical Trials for CM04S1
Ongoing Phase 2 trials for CM04S1, focusing on immunocompromised populations, with expected multiple clinical result presentations throughout 2025.
Increased Revenue from BARDA Contract
Revenue associated with the BARDA contract was $1.6 million in 2025, compared to zero in 2024, marking a significant financial improvement.
Strategic Partnerships and Collaborations
Ongoing discussions with various stakeholders, including WHO, White House, and Congressional Representatives, underscore GeoVax's strategic efforts for global development and commercialization.
Negative Updates
BARDA Stop Work Order
Received a Stop Work Order from BARDA, terminating the Project NextGen contract, impacting less than $750,000 annually in financial support.
Increased R&D and Administrative Expenses
R&D expenses increased by 21% to $5.4 million, and general and administrative expenses rose by 16% to $1.7 million in 2025.
Net Loss for Q1 2025
Reported a net loss of $5.4 million for Q1 2025, slightly lower than the $5.9 million loss in Q1 2024.
Cash Balance and Financing
Cash balances were $7.4 million as of March 31, 2025, with $6 million used in operating activities, necessitating continued exploration of funding strategies.
Company Guidance
During the GeoVax First Quarter 2025 Corporate Update Call, the company provided guidance on various fronts, highlighting key metrics and developments. GeoVax's first-quarter revenue from the BARDA contract was $1.6 million, marking a new revenue stream compared to zero in the previous year. Research and development expenses increased by 21% to $5.4 million, primarily due to costs related to the BARDA contract and ongoing vaccine programs. General and administrative expenses rose 16% to $1.7 million. The company reported a net loss of $5.4 million, or $0.45 per share, an improvement from a $5.9 million loss in 2024. Cash balances were $7.4 million as of March 31, 2025, up from $5.5 million at the end of 2024, due to $7.9 million in financing activities. The update also addressed the unexpected Stop Work Order from BARDA, estimating its financial impact to be less than $750,000 annually. The company remains focused on advancing its vaccine and therapeutic candidates, including GEO-CM04S1, GEO-MVA, and Gedeptin, while exploring strategic partnerships and additional funding opportunities to support its development programs.GeoVax Labs Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
GeoVax Labs Faces Contract Termination for COVID-19 Vaccine
Negative
Apr 14, 2025
On April 11, 2025, GeoVax Labs received a notification from Advanced Technology International to halt work on a Phase 2B clinical trial for their GEO-CM04S1 COVID-19 vaccine. The termination of the contract was decided by BARDA for governmental convenience, impacting the company’s ongoing project and possibly its strategic positioning in vaccine development.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges. While the BARDA award and vaccine advancements are significant positives, the company’s financial instability, negative cash flow, and bearish technical indicators weigh heavily on its overall score. The mixed sentiment from the earnings call, highlighting both achievements and setbacks, contributes to a cautious outlook.
To see Spark’s full report on GOVX stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.